The Department of Health of Moscow published a notice on holding a tender procedure for the conclusion of a state contract for the supply of medicines, which provides for counter-investment obligations of the supplier-investor for creation or modification and (or) development of production in Moscow on November 6th of 2020.
Moscow Endocrine Plant FSUE has won the competition on January 19th of 2021 (hereinafter referred to as the Company).
According to the terms of the competition, the company has to invest 1 billion rubles in the production localization of 20 anti-glaucoma, antibacterial, analgesic drugs, antidepressants, and neuroleptics in two years.
Contract Price is 1 092 458 499 rubles 58 kopecks.
The amount of investment is not less than 1,000,000,000 rubles 00 kopecks.
The Contract is valid until December 31st of 2030.
In accordance with the tender documentation, Moscow Endocrine Plant FSUE undertakes to:
to invest at least 1 billion rubles (accumulated total) in the creation or modification and (or) development of the production of medicines specified in Annex No. 1, as well as to ensure, in relation to medicines, the implementation of process operations for the production of finished dosage forms, packaging, manufacturing quality control no later than 24 (twenty-four) months from the date of conclusion of the Contract.
to ensure the implementation of process operations for the production of finished dosage forms, packaging, and manufacturing quality control within a period of no later than 36 months from the date of conclusion of the contract in respect of medicines.
to supply medicines produced in Moscow at the Facility from January 1st of 2023 to December 31st of 2030, in accordance with the Schedule of delivery of medicines, the production of which is being created/modified/developed in Moscow.
The contract is beneficial to both parties. The Moscow Endocrine Plant FSUE has a guaranteed sale of manufactured medicines to the Government of Moscow, at the expense of its own investments, expands the stock portfolio, implements the import substitution program of the Ministry of Industry and Trade of Russia, and sells drugs to other regions of the Russian Federation.
The Moscow government receives high-quality medicines at fixed prices for the next decade, new jobs, and increased tax revenues.
Comment type is not specified in the component properties.